

Clinical Trials on the AMS Website: Updated 01/27/11

Bladder & Urothelial:

Protocol No.

USOR06040

Title

Phase II Trial of Gemcitabine, Cisplatin, and Sunitinib in Patients with Advanced/Metastatic Urothelial Carcinoma

Brain:

Protocol No.

RTOG0825

Title

Phase III Double-Blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab vs. Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma

RTOG0539

Phase II Trial of Observational for Low-Risk Meningiomas and of Radiotherapy for Intermediate and High-Risk Meningiomas

Breast:

Protocol No.

USON09185

Title

An Open-Label, Expanded Access Protocol of Iniparib in Combination with Gemcitabine/Carboplatin in Patients with ER-, PR-, and HER2-Negative Metastatic Breast Cancer

USON07312

A Phase III Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer

TDM4370g

A Randomized, Multicenter, Phase III Open-Label study of the efficacy and safety of Trastuzumab-MCC-DM1 vs. Capecitabine + Lapatinib in Patients with Her2-Positive Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Trastuzumab-Based Therapy

Esophageal:

Protocol No.

RTOG0436

Title

A Phase III Trial Evaluating the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation for Patients with Esophageal Cancer Who Are Treated without Surgery

Gastric:

Protocol No.

USOR08055

Title

A Randomized, Multi-Center Phase III Study to Evaluate the Efficacy and Safety of Nilotinib vs. Imatinib in adult patients with Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST)

Cervical:

Protocol No.

RTOG0724

Title

Phase III Randomized study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy

RTOG0921

Phase II Study of Postoperative Intensity-Modulated Radiation Therapy (IMRT) with Concurrent Cisplatin and Bevacizumab followed by Carboplatin and Paclitaxel for Patients with Endometrial Cancer

Colorectal:

Protocol No.

USON10101

Title

A Randomized, Double-Blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients with Metastatic Colorectal Carcinoma Progressive during or Following First-Line Combination Therapy with Bevacizumab, Oxaliplatin, and a Fluoropyrimidine

Head & Neck Cancer:Protocol No.

USON09205

Title

A Randomized, Double-Blind, Phase 2 Safety Study of Cetuximab, using ImClone vs. Boehringer Ingelheim Manufacturing Processes, in Combination with Cisplatin of Carboplatin and 5-Fluorouracil in the First-Line Treatment of Patients with Locoregionally Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck

Multiple Myeloma:Protocol No.

USON09151

Title

Multiple Myeloma 2nd Line a Multicenter, Randomized, Double-Blind, Placebo Controlled Phase III Study of Panobinostat in Combination with Bortezomib and Dexamethasone in patients with relapsed Multiple Myeloma

Meningiomas:Protocol No.

RTOG0539

Title

Phase II Trial Observational for Low-Risk Meningiomas and of Radiotherapy for Intermediate and High-Risk Meningiomas

Non Small Cell Lung:Protocol No.

RTOG0617

Title

Phase III Comparison of Standard-dose vs. High-Dose Conformal RT with Concurrent and Consolidation Carboplatin/Paclitaxel in patients with Stage IIIA/IIIB (NSCLC)

USON09179

Open-Label, Multicenter, Randomized, Phase 2 Study of a Recombinant Human Anti-VEGFR-2 Monoclonal Antibody, IMC-1121B in Combination with Platinum-based Chemotherapy versus Platinum-based Chemotherapy Alone as First-line Treatment of Patients with Recurrent or Advanced Non-small Cell Lung Cancer (NSCLC)

USON10061

A Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer Following Disease Progression after One Prior Platinum- Based Therapy (NSCLC)

Pancreatic:Protocol No.

USON10087

Title

Randomized, Double-Blind Placebo-Controlled Phase II Study of the MEK inhibitor GSK1120212 plus Gemcitabine vs. Placebo plus Gemcitabine in Subjects with Metastatic Pancreatic Cancer

Prostate:Protocol No.

RTOG0815

Title

Phase II Prospective Randomized Trial of Dose-Escalated Radiotherapy with or without Short-Term Androgen Deprivation Therapy for Patients with Intermediate-Risk Prostate

RTOG0831

A Randomized, Double-Blinded, Placebo-Controlled Phase III Trial to Evaluate the Effectiveness of a Phosphodiesterase 5 inhibitor, Tadalafil, in Prevention of Erectile Dysfunction in Patients Treated with Radiotherapy for Prostate Cancer

USON09073

A Phase 3 Study to Evaluate the Efficacy and Safety of Docetaxel and Prednisone with or without Lenalidomide in Subjects with Castrate-Resistant Prostate Cancer (CRPC)

Renal Cell (Kidney):Protocol No.

USON10060

Title

AG-013736 (AXITINIB) for the Treatment of Metastatic Renal Cell Cancer

If you would like more information please contact Elizabeth Groh, Director of Clinical Research at Advanced Medical Specialties Tel 305-728-1882 or elizabethg@ams-ohrc.com.